Skip to main content

Mind Medicine Mindmed Inc(MNMD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

MindMed Provides Corporate Update and 2023 Outlook

Newswire.ca - Mon Jan 9, 2023

- Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023

- Company to initiate first clinical trial of MM-402 in 2023

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza